Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
"There’s a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively," said Dr. Thomas Haas, Vice President Science-to-Business Center Biotechnology of Creavis, the strategic research and development unit of Evonik.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.